GLP-1 RECEPTOR AGONIST MARKET ANALYSIS

Market Concentration and Competitive Landscape

Close-monitor your Competitor's Move, Request sample copy

Growing popularity of once-weekly dosing GLP-1 RA drugs

The once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) drugs are becoming increasingly popular among patients and physicians for treatment of type 2 diabetes. These drugs offer the clinical benefits of GLP-1 RAs through consistent weekly dosing rather than daily injections. The convenience of weekly injections has improved patient compliance and adherence to therapy. Drugs like semaglutide and dulaglutide, which come in prefilled pen devices, now allow patients to self-administer injections with ease on their scheduled day of the week. This shift towards longer-acting formulations has seen dramatic uptake rates for newer once-weekly GLP-1 RAs in major markets. For instance, sales data from the Australian Department of Health showed that the number of subsidized prescriptions for semaglutide had increased by over 250% from 2019 to 2021. In the U.S., weekly GLP-1 RAs dominate new prescription volumes for diabetes treatment as per the quarterly reports by Centers for Disease Control and Prevention. Drugmakers have also increased marketing efforts and educational campaigns around the simplicity and flexibility that weekly products offer. The promising efficacy and safety results from large outcome trials on cardiovascular risk reduction with semaglutide and dulaglutide have further strengthened the clinical value proposition for physicians. It is now recommended as the preferred injectable option after lifestyle and metformin. As per WHO, type 2 diabetes prevalence rises globally especially in developing countries that boosts need for better chronic disease management, and this boosts adoption of convenient and effective treatments like weekly GLP-1 RAs.